Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Edward_M._Kaye
|
| gptkbp:clinicalTrialPhase |
Phase 1/2 (as of 2023)
|
| gptkbp:developsTreatmentFor |
gptkb:Dravet_syndrome
|
| gptkbp:focusesOn |
genetic diseases
RNA-based medicines |
| gptkbp:foundedYear |
2014
|
| gptkbp:founder |
gptkb:Adrian_Krainer
|
| gptkbp:headquartersLocation |
gptkb:Bedford,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Stoke Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:STK-001
|
| gptkbp:numberOfEmployees |
approximately 100 (as of 2023)
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:researchInterest |
antisense oligonucleotides
upregulation of protein expression |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:STOK
|
| gptkbp:target |
rare neurological diseases
|
| gptkbp:website |
https://www.stoketherapeutics.com/
|
| gptkbp:bfsParent |
gptkb:Apple_Tree_Partners
|
| gptkbp:bfsLayer |
6
|